Hướng dẫn về việc sử dụng Apheresis điều trị trong thực hành lâm sàng—Cách tiếp cận dựa trên bằng chứng từ Ủy ban viết của Hiệp hội Apheresis Hoa Kỳ: Số đặc biệt thứ Sáu

Journal of Clinical Apheresis - Tập 28 Số 3 - Trang 145-284 - 2013
Joseph E. Schwartz1, Jeffrey L. Winters2, Anand Padmanabhan3, Rasheed A. Balogun4, Meghan Delaney5, Michael Linenberger6, Zbigniew M. Szczepiorkowski7, Mark E. Williams8, Yanyun Wu9, Beth H. Shaz10,11
1Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
2Division of Transfusion Medicine, Mayo Clinic Rochester, Minnesota
3BloodCenter of Wisconsin, Milwaukee, Wisconsin
4Division of Nephrology, University of Virginia, Charlottesville, Virginia
5Puget Sound Blood Center, Seattle, Washington
6Department of Medicine, Seattle Cancer Care Alliance, Seattle, Washington
7Department of Pathology and Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
8Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
9Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut
10Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia
11New York Blood Center, New York, New York

Tóm tắt

Ủy ban viết số đặc biệt JCA của Hiệp hội Apheresis Hoa Kỳ (ASFA) có nhiệm vụ xem xét, cập nhật và phân loại các chỉ định cho apheresis điều trị. Bắt đầu từ Số đặc biệt ASFA năm 2007 (Phiên bản thứ Tư), ủy ban đã tích hợp xem xét có hệ thống và phương pháp dựa trên bằng chứng vào việc phân loại và đánh giá các chỉ định. Phiên bản thứ Sáu của Số đặc biệt ASFA đã cải thiện quy trình sử dụng y học dựa trên bằng chứng trong các khuyến nghị bằng cách áp dụng nhất quán các định nghĩa của hệ thống phân loại và GRADE, nhưng loại bỏ tiêu chí "mức độ bằng chứng" (từ Liên minh Chăm sóc Sức khỏe Đại học) đã được sử dụng trong các phiên bản trước do sự dư thừa giữa hệ thống GRADE và Liên minh Chăm sóc Sức khỏe Đại học. Bố cục và khái niệm chung của bảng thông tin đã được sử dụng trong các phiên bản thứ Tư và thứ Năm đã được duy trì trong phiên bản này. Mỗi bảng thông tin tóm tắt ngắn gọn bằng chứng cho việc sử dụng apheresis điều trị trong một thể bệnh cụ thể. Bài viết này bao gồm 78 bảng thông tin (tăng từ 2010) cho các chỉ định điều trị trong các danh mục ASFA từ I đến IV, với nhiều bệnh được phân loại có nhiều biểu hiện/situation lâm sàng mà từng cái được đánh giá và phân loại riêng biệt. J. Clin. Apheresis 28:145–284, 2013. © 2013 Wiley Periodicals, Inc.

Từ khóa


Tài liệu tham khảo

10.1002/jca.20240

10.1002/jca.20134

10.1136/bmj.39489.470347.AD

10.1136/bmj.a744

Bassler D, 2008, Evidencebased medicine targets the individual patient. Part 2: guides and tools for individual decision‐making, ACP J Club, 149, 1

Bassler D, 2008, Evidence based medicine targets the individual patient. Part 1: how clinicians can use study results to determine optimal individual care, ACP J Club, 148, 2

10.1186/1472-6963-5-25

10.1378/chest.129.1.174

10.1002/jca.10029

McLeod B, 2010, Apheresis: Principles and Practice

10.1136/pmj.79.927.11

10.1016/j.transci.2007.11.002

10.1212/WNL.58.1.143

10.1542/peds.2004-2038

10.1002/jca.20022

10.1212/WNL.0b013e3181b879be

10.1097/WCO.0b013e3280f31b45

Murthy JM, 2002, Acute disseminated encephalomyelitis, Neurol India, 50, 238

RamachandraNair R, 2005, Plasmapheresis in childhood acute disseminated encephalomyelitis, Indian Pediatr, 42, 479

10.1212/WNL.56.10.1313

10.1111/j.1744-9987.2008.00617.x

10.1097/WCO.0b013e32833925ec

10.1212/01.wnl.0000259404.51352.7f

10.1007/s11940-001-0016-7

Assessment of plasmapheresis, 1996, Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology, Neurology, 47, 840

10.1212/WNL.35.8.1096

Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain‐Barre syndrome, 1997, Plasma Exchange/Sandoglobulin Guillain‐Barre Syndrome Trial Group, Lancet, 349, 225

The utility of therapeutic plasmapheresis for neurological disorders, 1986, NIH Consensus Development, JAMA, 256, 1333

Efficiency of plasma exchange in Guillain‐Barre syndrome: role of replacement fluids, 1987, French Cooperative Group on Plasma Exchange in Guillain‐Barre syndrome, Ann Neurol, 22, 753, 10.1002/ana.410220612

10.1136/adc.2004.065706

10.1016/j.braindev.2004.09.013

10.1212/WNL.0b013e318207b1f6

10.1111/j.1526-0968.2004.00183.x

10.1016/j.healun.2005.06.012

10.1097/NPT.0b013e31818e0882

10.1002/mus.21131

Hughes RA, 2012, Intravenous immunoglobulin for Guillain‐Barré syndrome, Cochrane Database Syst Rev, 7, CD002063

10.1097/TA.0b013e31804a7fc0

10.1111/j.1744-9987.2009.00730.x

10.1016/j.annemergmed.2005.05.008

10.1097/CND.0b013e3181f3dbbf

10.1212/WNL.0b013e31824de293

Raphaël JC, 2012, Plasma exchange for Guillain‐Barré syndrome, Cochrane Database Syst Rev, 7, CD001798

Szczeklik W, 2008, Acute respiratory failure in patients with Guillain‐Barre syndrome and myasthenic crisis treated with plasmapheresis in the intensive care unit, Pol Arch Med Wewn, 118, 239

10.1017/S1092852900013845

10.1056/NEJMra1114525

10.1002/(SICI)1098-1101(2000)15:1/2<74::AID-JCA6>3.0.CO;2-O

10.1186/1472-6963-11-101

10.1056/NEJM199204233261705

10.1097/01.MAT.0000093748.55874.BA

10.1002/jca.20064

10.1002/lt.500060122

10.1111/j.1572-0241.2001.03706.x

Silvestro G, 2000, A single institution's experience (1982–1999) with plasmaexchange therapy in patients with fulminant hepatic failure, Int J Artif Organs, 23, 454, 10.1177/039139880002300708

10.1097/01.sla.0000124298.74199.e5

10.1111/j.1872-034X.2008.00322.x

Horikoshi Y, 2012, Successful living donor liver transplantation for fulminant hepatic failure that manifested immediately after cesarean delivery, ASAIO J, 58, 174, 10.1097/MAT.0b013e3182444ed4

Huang YK, 2012, Randomized controlled study of plasma exchange combined with molecular adsorbent re‐circulating system for the treatment of liver failure complicated with hepatic encephalopathy, Hepatogastroenterology, 59, 1323

10.1016/j.transproceed.2010.09.073

10.1097/MCG.0b013e3181faefa3

10.1007/s10753-011-9333-5

10.1111/j.1749-6632.1999.tb08514.x

10.1007/s10047-004-0286-4

10.1016/j.bpg.2012.01.002

10.1111/j.1440-1746.2010.06574.x

10.1097/00003246-200107000-00014

10.1093/ndt/gfr115

10.1097/00000658-200109000-00015

10.1111/j.1525-1594.2005.29079.x

10.1002/(SICI)1098-1101(2000)15:1/2<53::AID-JCA5>3.0.CO;2-W

Blaha M, 2009, Cascade filtration in the therapy of the dry form of age‐related macular degeneration, Ther Apher Dial, 33, 453, 10.1111/j.1744-9987.2009.00752.x

10.1177/039139889501801208

Brunner R, 1996, Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption, and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome, Transfus Sci, 17, 493, 10.1016/S0955-3886(96)90083-1

10.1097/00006982-200009000-00009

Fell A, 2000, Effect of rheopheresis on visual function in patients with early age‐related macular degeneration, Invest Ophthalmol Vis Sci, 41, S181

10.1007/s00347-002-0614-0

10.1046/j.1526-0968.2000.004005348.x

10.1016/S1473-0502(03)00101-0

10.1111/j.1744-9987.2010.00807.x

10.1007/s00417-009-1113-7

10.1007/s00439-007-0406-3

10.1046/j.1526-0968.2003.00027.x

10.1097/IAE.0b013e31802e3e9b

Multicenter Investigation of Rheopheresis for AMD (MIRA‐1) Study Group, 2002, Multicenter prospective, randomized, double‐masked, placebo‐controlled study of rheopheresis to treat nonexudative age‐related macular degeneration: interim analysis, Trans Am Ophthalmol Soc, 100, 85

Pulido JS, 2006, Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA‐1) results, Trans Am Ophthalmol Soc, 104, 221

10.1002/jca.20047

10.1111/j.1755-3768.2009.01710.x

10.1001/archopht.116.5.583

Soudavar F, 1998, Changes of retinal haemodynamics after elimination of high molecular weight proteins and lipids in patients with age‐related macular degeneration (AMD), Invest Ophthalmol Vis Sci, 39, S386

Swartz M, 1999, Treatment of non‐exudative age‐related macular degeneration using membrane differential filtration apheresis, Invest Ophthalmol Vis Sci, 40, S319

10.1159/000014308

Widder RA, 2002, The treatment of age‐related macular degeneration (ARMD) with extracorporeal treatment procedures: A follow‐up of four years, Invest Ophthalmol Vis Sci, 43, 2906

Widder RA, 2000, Long‐term treatment of age‐related macular degeneration with extracorporeal apheresis, Ophthalmologe, 97, S172

Yeah JH, 2008, A case report of double‐filtration plasmapheresis for the treatment of age‐related macular degeneration, Ther Apher Dial, 12, 500, 10.1111/j.1744-9987.2008.00641.x

10.1002/jca.20031

10.1046/j.1526-0968.2002.00393.x

10.1111/j.1365-4362.1994.tb02935.x

10.1002/jca.20068

10.1200/JCO.2010.32.2271

10.1046/j.1526-0968.1999.00146.x

10.1002/jca.2920030407

10.1001/archneur.1983.04050110070012

Monstad, 1979, Plasma exchange in motoneuron disease, A controlled study. J Neurol, 221, 59

10.1001/archneur.1980.00500570059009

Lind, 2006, Clinical and histologic determinants of renal outcome in ANCA‐Associated vasculitis: a prospective analysis of 100 patients with severe renal involvement, J Am Soc Nephrol, 17, 2264, 10.1681/ASN.2005080870

de Lind van Wijngaarden RAF, 2007, Hagen EC; for the European Vasculitis Study Group (EUVAS): Chances for renal recovery for dialysis‐dependent ANCA associated glomerulonephritis, J Am Soc Nephrol, 2189, 10.1681/ASN.2007010066

10.1097/MOP.0b013e3283168e44

10.1046/j.1526-0968.2003.00089.x

10.1053/ajkd.2002.29876

10.1046/j.1440-1797.2003.00179.x

10.1007/s10157-004-0321-z

10.1046/j.1523-1755.2003.00843.x

10.1046/j.1526-0968.2001.005002134.x

10.1111/j.1744-9987.1997.tb00148.x

10.1053/j.ajkd.2003.08.015

Little MA, 2004, Rapidly progressive glomerulonephritis: current and evolving treatment strategies, J Nephrol, 17, S10

10.1136/ard.2008.088096

10.1681/ASN.2007010090

Kitazawa K, 2008, Lupus nephritis associated with positive MPO‐ANCA in a patient with underlying autoimmune hemolytic anemia, Clin Exp Nephrol, 12, 393, 10.1007/s10157-008-0058-1

10.2169/internalmedicine.45.1703

10.1053/j.ajkd.2003.08.015

Merkel PA, 2009, EULAR recommendations for the management of primary small and medium vessel vasculitis, Ann Rheum Dis, 68, 310, 10.1136/ard.2008.088096

10.1002/jca.20069

10.1177/039139889902200205

10.1053/j.ajkd.2010.10.049

10.1002/jca.20035

10.1053/ajkd.2002.29874

10.1097/00007890-198211000-00001

10.1111/j.1744-9987.2009.00687.x

10.1097/00005792-198507000-00003

10.1097/00007890-199704270-00001

10.1053/ajkd.2000.8993

10.1097/md.0b013e318067da56

10.7326/0003-4819-134-11-200106050-00009

10.1046/j.1523-1755.2003.00241.x

10.1159/000166666

Walker RG, 1985, Clinical and morphological aspects of the management of crescentic anti‐glomerular basement membrane antibody (anti‐GBM) nephritis/Goodpasture's syndrome, Q J Med, 54, 75

10.1111/j.1600-0609.1986.tb02663.x

10.3349/ymj.2002.43.2.274

10.1111/j.1537-2995.2011.03295.x

10.1111/j.1600-0609.1985.tb01711.x

10.1007/s00277-007-0304-8

Hunter C, 1981, Complete remission of idiopathic pure red cell aplasia. Case reports, S Afr Med J., 60, 68

Kiss JE, 2010, Apheresis: Principles and Practice, 3rd ed, 331

10.1056/NEJM198105283042205

10.2169/internalmedicine.36.487

OrR NaparstekE ManiN SlavinS.Treatment of pure red‐cell aplasia following major ABO‐mismatched T‐cell‐depleted bone marrow transplantation. Two case reports with successful response to plasmapheresis.Transpl Int1991;4:99–102.

10.1016/S0140-6736(94)92659-X

10.1016/j.hoc.2009.01.009

10.1182/blood-2011-12-274019

10.3324/haematol.13356

10.1016/S0140-6736(04)16302-2

10.1111/j.1600-0609.2004.00320.x

10.1046/j.1537-2995.2000.40050543.x

10.1002/jca.2920010206

10.1080/10245330601111540

AgliecoF ManickaratnamS BonaR KaplanAA.A case report of refractory warm autoimmune hemolytic anemia treated with plasmapheresis and rituximab.Ther Apher Dial2008;12:185–189.

Azuma E, 1996, Recurrent cold hemagglutinin disease following allogeneic bone marrow transplantation successfully treated with plasmapheresis, corticosteroid and cyclophosphamide, Bone Marrow Transplant, 18, 243

10.1182/blood-2009-09-242917

10.1002/ajh.10062

10.1111/j.1537-2995.2009.02383.x

10.1053/j.seminhematol.2005.04.003

10.1182/blood-2010-03-259325

10.1097/MOH.0b013e3282c8ca66

10.1097/00062752-200111000-00016

Powers A, 2009, Hematology, Basic Principles and Practice, 645

10.1182/blood-2003-10-3597

Rosse WF, 2002, Blood: Principles and Practice of Hematology, 2nd ed, 1859

10.1182/blood-2009-01-196329

RuivardM TournilhacO MontelS FouilhouxAC QuainonF LenatA TravadeP PhilippeP.Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case‐control study.J Clin Apher2006;21:202–206.

10.1053/j.seminhematol.2005.04.002

10.1046/j.1526-0968.2003.00004.x

10.1111/j.1399-3046.2007.00795.x

10.1002/(SICI)1098-1101(1998)13:1<32::AID-JCA7>3.0.CO;2-A

10.1086/319742

Herman JH, 2010, Autoimmunity in transfusion babesiosis: a spectrum of clinical presentations, J Clin Apher, 25:358

10.1053/tmrv.2002.33437

10.1002/jca.20197

10.1056/NEJMcpc079011

10.1016/j.idc.2008.03.010

10.1056/NEJMra1202018

10.1086/508667

10.1097/00004630-198505000-00007

Donati L, 1987, Prophylactic plasma exchange in burn treatment, Int J Tissue React, 9, 215

10.1097/BCR.0b013e318198a30d

10.1097/00004630-198901000-00004

10.1097/00005373-198409001-00009

10.1016/j.burns.2009.05.006

10.1001/archsurg.1984.01390130023004

10.1097/BCR.0b013e31815f3876

10.1097/00004630-198605000-00006

Stratta RJ, 1983, Plasma‐exchange therapy during burn shock, Curr Surg, 40, 429

10.1097/00005373-198601000-00002

10.1097/00000658-197503000-00019

Warden GD, 1984, The effect of exchange therapy on postburn lymphocyte suppression, Surgery, 96, 321

10.1097/00005373-198310000-00018

Ballew CC, 2005, Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation, Am J Crit Care, 14, 46, 10.4037/ajcc2005.14.1.46

10.1034/j.1399-0012.2000.140211.x

10.1056/NEJM199812103392404

10.1016/j.healun.2010.08.020

10.1016/j.transproceed.2012.01.086

10.1016/S1473-0502(02)00010-1

10.1016/j.healun.2008.02.015

10.1016/S0041-1345(98)01471-7

Hodge EE, 1994, Pretransplant removal of anti‐HLA antibodies by plasmapheresis and continued suppression on cyclosporine‐based therapy after heart‐kidney transplant, Transplant Proc, 26, 2750

10.1016/j.healun.2007.07.011

10.1016/j.athoracsur.2004.03.031

John R, 1999, Intravenous immunoglobulin reduces anti‐HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular device recipients, Circulation, 100, 229, 10.1161/circ.100.suppl_2.Ii-229

10.1016/j.healun.2008.12.017

10.1016/j.healun.2005.10.004

10.1067/mtc.2003.168

10.1097/01.TP.0000157278.02848.C7

Larson DF, 1999, Plasmapheresis during cardiopulmonary bypass: a proposed treatment for presensitized cardiac transplantation patients, J Extracorporeal Tech, 31, 177, 10.1051/ject/1999314177

10.1111/j.1399-0012.2006.00509.x

10.1016/S1053-2498(01)00322-9

10.1016/j.healun.2008.06.004

10.1016/S0041-1345(00)02605-1

10.1097/00007890-199402000-00015

10.1097/TP.0b013e31823f7eea

10.1016/S1053-2498(99)00022-4

Pollock‐BarZiv SM, 2007, Pediatric heart transplantation in human leukocyte antigen‐sensitized patients. Evolving management and assessment of intermediate‐term outcomes in a high‐risk population, Circulation, 116, I‐172

10.1016/j.healun.2005.09.003

10.1111/j.1744-9987.1997.tb00030.x

10.1016/j.healun.2005.03.019

10.1016/j.transproceed.2006.10.060

Asherson RA, 1992, The catastrophic antiphospholipid syndrome, J Rheumatol, 19, 508

10.1016/j.autrev.2004.03.007

10.1191/0961203303lu394oa

10.1097/00005792-199805000-00005

10.1097/00005792-200111000-00002

10.1177/0961203309361353

10.1016/j.jaut.2009.02.008

10.1136/ard.2004.025759

10.1016/j.ijgo.2007.05.045

10.1038/ncprheum1017

10.1055/s-0028-1082274

10.1016/j.semarthrit.2012.05.005

10.1002/(SICI)1098-1101(1999)14:4<171::AID-JCA3>3.0.CO;2-5

Furmańczyk A, 2009, Catastrophic antiphospholipid syndrome, Pol Arch Med Wewn, 119, 427

10.1038/ncprheum0511

10.1002/art.34440

10.1002/1096-8652(200010)65:2<154::AID-AJH11>3.0.CO;2-A

10.1016/j.transci.2004.10.025

10.1177/0885066606287041

10.1016/j.eplepsyres.2008.03.007

10.1212/WNL.46.1.242

10.1097/00019052-199604000-00015

10.1111/j.1528-1157.1997.tb01096.x

10.1212/WNL.51.1.302

10.1093/brain/awh415

10.1212/01.WNL.0000099074.04539.E0

10.1097/00019052-199604000-00002

10.1212/WNL.8.6.435

GuimaraesCA SouzaEA MontenegroMA MarquesJF Jr. CendesF GuerreiroMM.Rasmussen's encephalitis: the relevance of neuropsychological assessment in patient's treatment and follow up.Arq Neuropsiquiatr2002;60(2-B):378–381.

10.1017/S0317167100011495

10.1126/science.8036512

10.1002/mus.21277

10.1056/NEJM198602203140801

10.1002/ana.410360607

10.1093/brain/119.4.1055

10.1056/NEJMra041347

10.1136/jnnp.2005.065441

Mehndiratta MM, 2012, Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev, 9, CD003906

10.1002/pbc.22084

10.1016/j.clinthera.2009.01.005

Clark JA, 2010, Topical bovine thrombin: a 21‐year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System, Pharmacoepidemiol Drug Saf., 107, 10.1002/pds.1874

Eby C, 2003, Hemostatic complications associated with paraproteinemias, Curr Hematol Rep, 2, 388

Francesconi M, 1982, Plasmapheresis: its value in the management of patients with antibodies to factor VIII, Haemostasis, 11, 79

10.1055/s-0029-1214150

10.1097/01.moh.0000139998.68132.d2

10.1111/j.1423-0410.1991.tb00954.x

10.1016/j.transci.2007.04.003

Huguet HC, 2004, Extracorporeal adsorption of anti‐factor VIII allo‐antibodies on randomly functionalized polystyrene resins, Thromb Haemost, 91, 259, 10.1160/TH03-07-0430

10.1046/j.1365-2141.2001.02510.x

Kreuz W, 2003, Epidemiology of inhibitors and current treatment strategies, Haematologica, 88

10.1002/pbc.22084

10.1046/j.1537-2995.2002.00011.x

10.1046/j.1365-2141.1999.01220.x

10.1182/blood-2010-11-297580

10.1016/0955-3886(92)90176-H

10.1159/000341913

10.1182/blood-2003-11-4035

10.1001/archderm.139.3.391

10.1046/j.1537-2995.1980.20280169957.x

10.1002/art.34331

10.1046/j.1526-0968.2002.00400.x

Russo GE, 1996, Haemorheological changes in mixed cryoglobulinaemia during apheresis treatment, Transfus Sci, 17, 499, 10.1016/S0955-3886(96)90084-3

10.1097/00002480-199507000-00021

10.1002/jca.20222

10.1182/blood-2011-12-396028

10.1016/j.jaad.2008.05.038

10.1111/j.1365-2133.2009.09081.x

10.1016/S1473-0502(02)00010-1

10.1016/S1473-0502(02)00103-9

10.1016/j.clon.2004.11.010

10.1111/j.1365-2133.2005.06857.x

10.1111/j.1600-0781.2007.00300.x

10.1200/JCO.2010.32.0630

10.1016/j.jaad.2010.08.037

10.1182/blood-2009-07-202895

10.1001/archdermatol.2011.232

Sanli H, 2011, The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome, J Drugs Dermatol, 10, 403

10.1111/j.1365-2133.2007.08415.x

10.1016/j.transci.2011.10.029

10.1016/j.ejca.2006.01.025

Wain EM, 2005, A randomized, open, crossover study to compare the efficacy of extracorporeal photopheresis with methotrexate in the treatment of primary cutaneous T‐cell lymphoma, Brit J Dermatol, 153, 10

10.1097/01.cco.0000410158.56500.c4

10.1016/j.transci.2007.01.008

10.1056/NEJM199205213262102

10.1007/s00392-011-0287-2

10.1007/s00392-010-0162-6

10.1002/jca.20137

10.1016/j.ejheart.2005.10.019

10.1358/mf.2001.23.3.627947

10.1002/jca.20130

Dandel M, 2010, Efficacy of immunoadsorption as bridge‐to‐transplant therapy in patients with idiopathic dilated cardiomyopathy and evidence of beta‐1 adrenoreceptor autoantibodies, J Heart Lung Transplant, 20, S1630

10.1093/eurjhf/hfs123

10.1002/jca.20204

10.1002/jca.20263

10.1161/01.CIR.95.8.1994

10.1046/j.1526-0968.2000.00177.x

10.1016/j.ijcard.2004.03.001

10.1016/j.ijcard.2006.05.014

10.1016/S0735-1097(00)00568-4

10.1016/S0735-1097(01)01794-6

10.1002/jca.20127

10.1016/j.ahj.2010.01.012

10.1007/s10198-003-0202-5

10.1080/08916930802031603

10.1007/s00109-007-0263-5

10.1016/j.cardfail.2008.02.016

10.1016/S0896-8411(03)00042-8

10.1161/01.CIR.101.4.385

10.1002/jca.20268

Nagatomo Y, 2008, Short‐term experience of immunoadsorption therapy for refractory heart failure due to dilated cardiomyopathy, J Card Fail, 14, S148, 10.1016/j.cardfail.2008.07.075

10.1002/jca.20050

10.1016/S0735-1097(01)01309-2

10.1161/01.CIR.0000036746.49449.64

10.1016/j.ahj.2004.11.002

10.1038/clpt.2009.246

10.1016/j.ahj.2006.06.027

10.1161/01.CIR.103.22.2681

10.1016/j.jacc.2004.04.055

10.1111/j.1744-9987.2006.00343.x

10.1111/j.1365-2362.2006.01603.x

10.1007/s00246-008-9332-y

10.1002/jca.20264

10.1111/j.1365-2362.2010.02314.x

10.1002/jca.20254

10.1016/S0735-1097(96)00388-9

10.1097/00002480-198907000-00057

10.1177/000331979304400308

10.1046/j.1526-0968.2003.00070.x

10.1046/j.1525-1594.2002.06837.x

10.1016/S0735-1097(02)01961-7

Beigel R, 2009, Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature, J Clin Apher, 24:219

10.1034/j.1600-0412.1998.770605.x

10.1258/000456306778904641

Blazek M, 2007, Primary hemostasis in patients treated with LDL‐apheresis for severe familiar hypercholesterolemia: a prospective pilot trial using PFA‐100 analysis to rationalize therapeutic LDL‐apheresis procedure, Hematology, 12, 571, 10.1080/10245330701448370

10.1111/j.1744-9987.2009.00667.x

10.1111/j.1526-0968.2003.00120.x

10.1046/j.1526-0968.2003.00057.x

10.1046/j.1526-0968.2003.00064.x

10.1046/j.1526-0968.2001.00340.x

10.1111/j.1525-1594.1993.tb00609.x

10.1111/j.1525-1594.1997.tb00511.x

10.1002/jca.2920070206

10.1016/0021-9150(94)90106-6

Dairou F, 1998, Plasma exchange treatment for severe familial hypercholesterolemia: A comparison of two different techniques, Infus Ther, 23, 152

10.1046/j.1365-2362.1998.00395.x

10.1016/S0002-9149(97)00947-8

10.1007/s11883-000-0064-6

10.1097/00041433-199612000-00007

10.1002/(SICI)1098-1101(1996)11:3<128::AID-JCA2>3.0.CO;2-D

10.1016/0002-9149(94)90461-8

10.1097/00041433-199402000-00011

Gordon B, 1993, LDL apheresis in the treatment of severe hyperlipidemia, Primary Cardiol, 19, 53

10.1016/0002-9343(77)90874-9

10.1002/jca.20006

10.1016/S0002-9149(02)03248-4

10.1002/jca.20000

10.1067/mpd.2002.124384

10.1046/j.1526-0968.2002.00427.x

10.1046/j.1526-0968.2003.00072.x

10.1002/jca.2920110304

10.1002/jca.20135

Kamanabroo D, 1988, Plasma exchange in Type II hypercholesterolemia, Prog Clin Biol Res, 255, 347

Kamimura M, 2002, Improvements in artery occlusion by low‐density lipoprotein apheresis in a patient with peripheral arterial disease, Ther Apher, 6, 467, 10.1046/j.1526-0968.2002.00470.x

10.1046/j.1526-0968.2003.00077.x

10.1046/j.1526-0968.2003.00063.x

10.1097/00001721-199909000-00004

10.1046/j.1526-0968.2003.00062.x

10.1016/j.transci.2004.01.008

10.1007/BF00212983

10.1002/jca.10055

10.1046/j.1365-2796.1999.00466.x

10.1016/0021-9150(93)90068-6

2010, Koziolek MJ, Henning U, Zapf A, Bramlage C, Grupp C, Armstrong VW, Strutz F, Muller GA, Retrospective analysis of long‐term lipid apheresis in a single center. Ther Apher Dial (, 143

10.1177/039139880402700209

10.1111/j.1525-1594.2004.29007.x

10.1161/01.CIR.93.10.1826

10.7326/0003-4819-125-12-199612150-00001

Lane D, 1995, Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy, Atherosclerosis, 11, 203, 10.1016/0021-9150(94)05484-Z

Lane D, 1994, Changes in plasma lipid and apolipoprotein levels between heparin‐induced extracorporeal low‐density lipoprotein precipitation (HELP) treatments, Am J Cardiol, 75, 1124, 10.1016/S0002-9149(99)80743-7

10.1016/0002-9149(93)90830-6

10.1111/j.1365-2796.1993.tb00673.x

10.1016/S0002-9149(98)00692-4

10.1016/0021-9150(87)90089-X

Masin V, 2007, Optimization of therapeutic procedure during LDL‐apheresis verification of the computerized model in clinical practice, Transfus Apher Sci, 36, 39, 10.1016/j.transci.2006.10.004

10.1111/j.1525-1594.1994.tb03302.x

10.1016/S0735-1097(02)01955-1

10.1046/j.1526-0968.2003.00051.x

10.1111/j.1744-9987.2006.00441.x

10.1177/000331979804900302

10.1016/j.amjcard.2010.01.018

10.1016/S0021-9150(98)00328-1

10.1111/j.1525-1594.1996.tb04454.x

10.1016/j.transci.2007.08.009

10.1016/j.amjcard.2007.06.033

10.1016/j.atherosclerosis.2004.01.017

10.1111/j.1525-1594.2003.07200.x

10.1002/jca.20149

10.1111/j.1744-9987.2008.00574.x

10.1046/j.1526-0968.2000.004005382.x

10.1016/S0021-9150(98)00092-6

Park JW, 1995, Regression of transplant coronary artery disease during chronic HELP therapy: a case study, Atherosclerosis, 115, 1, 10.1016/0021-9150(95)91034-O

Postiglione A, 1988, From plasma‐exchanged to LDL‐apheresis: new developments in the treatment of familial hypercholesterolemia, Contrib Infus Ther, 23, 74

10.1159/000418561

10.1046/j.1526-0968.2003.00054.x

10.1002/jca.20036

Saku K, 1998, Long‐term effect of low‐density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow‐up study using coronary angiography, J Cardiol, 31, 239

10.1111/j.1525-1594.1996.tb04452.x

Schwandt P, 2003, Lipid apheresis: the only therapeutic option for a very small group of cardiovascular patients with high low‐density lipoprotein cholesterol or lipopoprotein(a) blood concentrations, Ther Apher Dial, 7, 283, 10.1046/j.1526-0968.2003.00061.x

10.1111/j.1525-1594.1996.tb04449.x

10.1046/j.1526-0968.2001.00316.x

10.1016/S0049-3848(00)00301-7

10.1038/ncpcardio0836

10.1016/j.transci.2009.10.003

10.1111/j.1537-2995.2009.02135.x

10.1016/j.transci.2003.12.002

10.1016/S0140-6736(81)91213-7

10.1161/01.CIR.95.1.76

10.1111/j.1537-2995.2010.02911.x

10.1111/j.1744-9987.2006.00315.x

10.1046/j.1526-0968.2003.00076.x

10.1016/0021-9150(92)90170-L

10.1016/j.atherosclerosis.2006.02.030

10.1097/MOL.0b013e3283402f53

10.1016/S0021-9150(02)00251-4

10.1016/j.atherosclerosis.2008.02.009

10.1136/hrt.43.6.680

10.1136/bmj.291.6510.1671

Thompson GR, 1988, Plasma exchange and LDL apheresis, Prog Clin Biol Res, 255, 311

Thompson GR, 1989, Plasmapheresis in familial hypercholesterolemia, Arteriosclerosis, 9, 152

10.1016/j.atherosclerosis.2008.02.009

10.1016/S0140-6736(95)92961-4

10.1016/j.atherosclerosis.2009.06.010

10.1016/j.ymgme.2005.11.003

Aalst‐Cohen E, 2004, Clinical, diagnostic and therapeutic aspects of (inherited) hypercholesterolemia, Drug Discov Today, 1, 165, 10.1016/j.ddmec.2004.09.007

Baeyer H, 2000, Outcome of patients on long term low‐density lipop‐rotein apheresis with membrane differential filtration: a case study in trhee patients 14 years on treatment, Ther Apher, 4, 386, 10.1046/j.1526-0968.2000.004005386.x

10.1002/jca.10071

10.1002/jca.2920040205

10.1046/j.1526-0968.2003.00069.x

10.1111/j.1525-1594.1992.tb00290.x

10.1016/j.amjcard.2005.06.012

10.1016/S0022-3476(95)70400-0

10.1111/j.1526-0968.2001.00318.x

Braun N, 2008, Immunosuppressive treatment for focal segmental glomerulosclerosis in adults, Cochrane Database Syst Rev, CD003233

Cameron JS, 2003, Focal segmental glomerulosclerosis in adults, Nephrol Dial Transplant, 18, vi45, 10.1093/ndt/gfg1058

10.1111/j.1600-6143.2009.02580.x

10.1056/NEJMra1106556

10.1016/S0272-6386(99)70010-7

Deegens JK, 2008, Review on diagnosis and treatment of focal segmental glomerulosclerosis, Neth J Med, 66, 3

10.1016/j.transproceed.2006.06.069

10.1111/j.1600-6143.2005.01112.x

10.1111/j.1399-3046.2010.01303.x

10.1016/j.transproceed.2011.03.025

10.1111/j.1399-3046.2011.01478.x

10.1111/j.1744-9987.2010.00828.x

10.1111/j.1525-139X.2011.01031.x

10.1111/j.1600-6143.2009.02550.x

10.1111/j.1399-3046.2007.00880.x

10.2215/CJN.03800609

10.1093/ndt/gfh320

10.1517/14656566.6.9.1539

10.1111/j.1432-2277.2009.00977.x

Newstead CG, 2003, Recurrent disease in renal transplants, Nephrol Dial Transplant, 18, vi68

10.1093/ndt/gfk005

10.1111/j.1399-0012.2010.01279.x

10.1056/NEJM199604043341402

10.1111/j.1399-0012.2008.00908.x

Sharma M, 1999, "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma, J Am Soc Nephrol, 10, 552, 10.1681/ASN.V103552

10.1038/sj.ki.5000160

10.1111/j.1525-1594.2010.01068.x

10.1016/j.transproceed.2005.02.061

10.1111/j.1537-2995.2010.02712.x

10.1038/sj.bmt.1703871

10.1097/MPH.0b013e31814d66f5

10.1038/sj.bmt.1703830

10.1002/jca.20084

10.1038/bmt.2008.174

10.1182/blood-2005-09-3907

10.1001/archderm.140.6.763

Dignan FL, 2012, Efficacy of biomonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD, Bone Marrow Transplant, 47:824

10.1002/pbc.20870

10.1182/blood-2008-03-141481

10.1038/sj.bmt.1704984

Garban F, 2005, Extracorporeal chemophototherapy for the treatment of graft‐versus‐host disease: hematologic consequences of short‐term, intensive courses, Haematologica, 90, 1096

10.1016/j.transci.2007.01.002

10.3324/haematol.12688

Greinix HT, 2006, The effect of intensified extracorporeal photochemotherapy on long‐term survival in patients with severe acute graft‐versus‐host disease, Haematologica, 91, 405

10.1016/j.bbmt.2011.05.004

10.1038/bmt.2011.35

10.1016/j.transci.2004.02.003

10.1016/j.bbmt.2009.06.007

10.1016/S1473-0502(02)00102-7

10.1111/j.1537-2995.2007.01469.x

10.1038/bmt.2010.152

10.1016/j.bbmt.2012.04.005

10.1046/j.1365-2141.2003.04401.x

10.1177/112067210701700615

10.1002/jca.20159

10.1038/bmt.2008.221

10.1111/j.1537-2995.2009.02577.x

10.1111/j.1744-9987.2007.00421.x

10.1111/j.1365-2141.2005.05586.x

10.1182/blood-2002-11-3351

10.1016/j.transci.2011.10.028

10.1016/j.bbmt.2010.05.011

10.1046/j.1365-2141.2001.02587.x

10.1182/blood.V98.6.1687

10.1111/j.1537-2995.2011.03069.x

10.1182/blood.V79.11.3076.bloodjournal79113076

10.1038/sj.bmt.1702121

10.1182/blood.V96.3.1150

10.1038/bmt.2011.135

10.3324/haematol.13356

10.1111/j.1537-2995.2007.01289.x

10.1111/j.1432-2277.2003.tb00303.x

10.1007/s00467-012-2130-z

10.1186/1750-1172-6-60

10.2215/CJN.10181110

10.1056/NEJMra0902814

10.1681/ASN.2008080906

10.1111/j.1525-139X.2011.01022.x

10.1038/nrneph.2012.214

10.1016/S0140-6736(11)61145-8

10.1111/j.1365-2141.2008.07317.x

10.1001/jama.290.10.1360

10.1016/S0140-6736(11)61253-1

10.1136/bmj.e4565

10.2215/CJN.08921209

10.1002/jca.21208

10.1038/nrneph.2012.196

10.1007/s00467-008-0886-y

10.1053/j.ajkd.2011.12.015

Chalopin JM, 1980, Treatment of IgA nephropathies with plasma exchanges alone, Kidney Int, 18, 135

10.1007/s004670000477

10.5414/CNP61213

10.1159/000223237

10.1046/j.1442-200X.2003.01748.x

Gaskell H, 1985, Henoch‐Schönlein purpura with severe ileal involvement responding to plasmapheresis, Int J Artif Organs, 8, 163, 10.1177/039139888500800311

10.1136/adc.75.3.186

10.1016/S0272-6386(99)70178-2

Kauffmann RH, 1981, Plasmapheresis in rapidly progressive Henoch‐Schonlein glomerulonephritis and the effect on circulating IgA immune complexes, Clin Nephrol, 16, 155

10.1007/s00467-004-1514-0

10.1111/j.1600-6143.2007.02022.x

10.1016/S0140-6736(79)92505-4

McKenzie PE, 1979, Plasmapheresis in glomerulonephritis, Clin Nephrol, 12, 97

Pasquali S, 1983, Plasma exchange in rapidly progressive glomerulonephritis, Eur J Clin Invest, 13, A44

Pussell BA, 1978, Value of immune–complex assays in diagnosis and management. Lancet, 2, 359

10.1007/s10067-005-0113-1

10.1097/SMJ.0b013e3180f62d0f

10.1007/s00467-007-0498-y

10.1007/s00467-004-1673-z

Wortmann SB, 2006, Refractory severe intestinal vasculitis due to Henoch‐Schönlein Purpura: successful treatment with plasmapheresis, Acta Pediatr, 95, 622, 10.1080/08035250500509180

Abdel‐Razeq HN, 2004, Treating heparin‐induced thrombocytopenia, The unconventional way! Saudi Med J, 25, 1258

10.1002/jca.20099

Blakeman B, 1999, Management of heparin‐induced thrombocytopenia: a cardiovascular surgeon's perspective, Semin Hematol, 36, 37

10.1016/0049-3848(88)90111-9

10.1093/ajcp/96.3.394

Chan MY, 2008, Identification and treatment of arterial thrombophilia, Curr Treat Options Cardiovasc Med, 10, 3, 10.1007/s11936-008-0001-5

10.1111/j.1538-7836.2010.04059.x

10.1213/ANE.0b013e3181c427d5

10.1002/jca.20289

10.1111/j.1540-8191.2001.tb00527.x

10.1177/0267659109106109

10.1016/j.athoracsur.2006.09.038

Koster A, 2001, Some new perspectives in heparin‐induced thrombocytopenia type II, J Extra Corpor Technol, 33, 193, 10.1051/ject/2001333193

10.1510/icvts.2008.193177

10.1378/chest.11-2303

Manzano L, 1990, Plasmapheresis in heparin‐induced thrombocytopenia and thrombosis, Stroke, 21, 1236, 10.1161/str.21.8.1236b

10.1016/j.cll.2009.03.003

10.1182/blood-2005-04-1546

10.1016/j.hlc.2012.02.005

10.2165/00002018-200326090-00003

Nagle EL, 2011, Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy, Ann Pharmacother, 45, e47, 10.1345/aph.1P785

10.1002/ajh.2830280318

10.1592/phco.26.4.576

10.1056/NEJM200008173430718

10.1046/j.1365-2141.1998.0847a.x

10.1097/CCM.0b013e3181de0b88

Robinson JA, 1999, Plasmapheresis in the management of heparin‐induced thrombocytopenia, Semin Hematol, 36, 29

10.1182/blood-2008-03-145243

10.1213/01.ANE.0000114072.71353.D5

Thorp D, 1990, Plasma exchange and heparin‐induced thrombocytopenia, Prog Clin Biol Res, 337, 521

10.1213/00000539-198605000-00018

10.1016/j.jtcvs.2010.06.018

10.1111/bjh.12059

10.1213/ANE.0b013e3181c3c1cd

10.1182/blood-2010-01-261875

10.1016/S0955-3886(00)00088-6

10.1182/asheducation-2006.1.36

10.7326/0003-4819-129-11_Part_2-199812011-00008

10.1038/ng0896-399

10.1157/13092766

10.1046/j.1423-0410.2000.7910040.x

Mariani R, 2005, Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage, Haematologica, 90, 717

10.1002/jca.10024

10.1056/NEJMra031573

10.1089/10906570050114867

10.1016/j.transci.2007.03.005

10.1016/j.transci.2009.01.008

10.1111/j.1537-2995.2011.03292.x

10.1136/bmj.c7251

10.1183/09031936.00057711

10.1016/j.transci.2006.03.001

10.1111/j.1537-2995.2007.01406.x

10.1200/JCO.1985.3.12.1590

10.1002/mpo.2950150503

10.1002/pbc.21628

10.1002/ajh.20939

10.1002/ajh.10155

10.1002/jca.20290

10.1182/blood.V79.4.871.bloodjournal794871

10.1016/j.blre.2012.01.003

10.3109/10428190109097677

10.1055/s-0029-1239533

10.1002/cncr.23581

10.1002/ajh.21006

10.1002/pbc.20178

10.1016/j.leukres.2008.01.004

10.1200/JCO.1988.6.9.1425

10.1111/j.1600-0609.2005.00421.x

10.1002/ajh.21418

10.1200/JCO.2011.36.2756

10.1111/j.1442-2042.2004.00872.x

10.1046/j.1365-2141.1997.1943011.x

10.1097/00043426-200307000-00015

10.1111/j.1744-9987.2007.00417.x

10.1080/1042819022386671

10.1182/blood.V97.7.2121

Tan D, 2005, Therapeutic leukapheresis in hyperleukocytic leukaemias–the experience of a tertiary institution in Singapore, Ann Acad Med Singapore, 34, 229, 10.47102/annals-acadmedsg.V34N3p229

10.1007/s002770000162

10.1002/ajh.2830270109

Bolan C, 2002, Intensive, long‐term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy, J Clin Endocrinol Metab, 87, 380, 10.1210/jcem.87.1.8176

Chait A, 1992, Chylomicronemia syndrome, Adv Intern Med, 37, 249

10.3748/wjg.v10.i15.2272

10.1016/S1567-5688(09)71810-0

10.1097/00006676-199607000-00013

10.1002/jca.20224

10.1002/jca.20192

10.1016/0016-5085(93)90366-K

10.1002/jca.10063

10.1002/jca.10047

10.3181/00379727-80-19629

10.4065/mcp.2010.0304

10.1111/j.0954-6820.1985.tb01646.x

Bloch KJ, 1973, Hyperviscosity syndromes associated with immunoglobulin abnormalities, Semin Hematol, 10, 113

Buskard NA, 1977, Plasma exchange in the long‐term management of Waldenstrom's macroglobulinemia, Can Med Assoc J, 117, 135

10.1001/jama.1965.03080190030008

Hoffkes HG, 1995, Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenstrom's type, Clin Nephrol, 43, 335

10.1055/s-2007-994921

MacKenzie MR, 1972, Macroglobulinemia: an analysis for forty patients, Blood, 39, 874, 10.1182/blood.V39.6.874.874

10.1167/iovs.07-1254

10.1172/JCI108568

Mod A, 1981, Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases, Haematologia (Budap), 14, 49

10.1136/bmj.3.5776.664

Reinhart WH, 1992, Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenstrom and multiple myeloma: influence on blood rheology and the microcirculation, J Lab Clin Med, 119, 69

10.1001/jama.245.6.606

Russell JA, 1977, Plasma exchange in malignant paraproteinemias, Exp Hematol, 5, 105S

Skoog WA, 1962, Metabolic balance study of plasmapheresis in a case of Waldenstrom's macroglobulinemia, Blood, 19, 425, 10.1182/blood.V19.4.425.425

10.7326/0003-4819-58-5-789

10.1182/blood-2011-04-347690

10.1177/039139888500800312

10.1007/s002770050195

10.1046/j.1537-2995.1986.26486262750.x

10.1111/j.1744-9987.1997.tb00057.x

10.1046/j.1523-1755.2003.00843.x

Jindal K, 1999, management of idiopathic cresentic and diffuse proliferative glomerulonephritis: evidence‐based recommendations, Kidney Int, 55, S33, 10.1046/j.1523-1755.1999.07005.x

Levy JB, 1997, Still a role for plasma exchange in rapidly progressive glomerulonephritis?, J Nephrol, 10, 7

Little MA, 2004, Rapidly progressive glomerulonephritis: Current and evolving treatment strategies, J Nephrol, 17, S10

10.1007/BF01711654

10.1093/oxfordjournals.ndt.a091855

Sakellariou G, 1985, Plasma exchange (PE) treatment of rapidly progressive glomerulonephritis (RPGN), Life Support Syst, 3, 365

10.1177/039139889902200205

Stratta P, 1983, Plasma exchange in immune complex glomerulonephritis: clinical and immunological correlations, Int J Artif Organs, 6, 27

Thysell H, 1983, Improved outcome in rapidly progressive glomerulonephritis by plasma exchange treatment, In J Artif Organs, 6, 11

Walters G, 2008, Interventions for renal vasculitis in adults, Cochrane Database Syst Rev, 16, CD003232

10.1001/archinte.141.2.175

10.1053/ajkd.2002.29874

Berchtold P, 1989, Therapy of chronic idiopathic thrombocytopenic purpura in adults, Blood, 74, 2309, 10.1182/blood.V74.7.2309.2309

10.1111/j.1525-1594.1988.tb02809.x

10.1046/j.1537-2995.1984.24585017826.x

10.1016/S0955-3886(98)00044-7

10.1046/j.1365-2141.1998.00568.x

10.1182/blood-2004-12-4598

10.1001/archinte.160.11.1630

10.1097/00000441-198712000-00010

Handelsman H, 1990, Protein A columns for the treatment of patients with idiopathic thrombocytopenic purpura and other indications, Health Technol Assess Rep, 1

Guthrie TH, 1989, Immune thrombocytopenia purpura: a pilot study of staphylococcal protein A immunomodulation in refractory patients, Semin Hematol, 26, 3

10.1097/00043426-198623000-00009

10.1002/ajh.10312

10.1046/j.1537-2995.1981.21381201800.x

Nakhoul IN, 2006, Management of adult idiopathic thrombocytopenic purpura, Clin Adv Hematol Oncol, 4, 136

10.1182/blood-2010-08-302984

10.1111/j.1600-0609.1987.tb00177.x

10.1182/blood-2009-06-225565

10.1111/j.1537-2995.2004.04333.x

10.1097/00002030-199110000-00017

10.1182/blood.V79.9.2237.2237

10.1001/archinte.140.8.1101

10.1097/00007611-199702000-00016

Chalopin JM, 1984, Plasma exchange in severe IgA nephropathies: a prospective randomized trial, Ann Med Interne, 135, 33

Chalopin JM, 1983, Plasma exchange and IgA nephropathies, Eur J Clin Invest, 13, A45

10.1002/(SICI)1098-1101(1999)14:4<185::AID-JCA6>3.0.CO;2-K

10.1111/j.1525-1594.1985.tb04400.x

10.1159/000183527

Coppo R, 1985, Plasma exchange in primary IgA nephropathy and Henoch‐Schönlein syndrome nephritis, Plasma Ther Transfus Technol, 6, 705

10.1053/j.ajkd.2011.05.033

10.1007/s00467-006-0428-4

Hene RJ, 1982, Plasmapheresis in nephropathy of Henoch‐Schönlein purpura and primary IgA nephropathy, Kidney Int, 22, 409

10.1016/S0272-6386(87)80014-8

10.1002/jca.2920050303

10.1016/S0272-6386(85)80134-7

Roccatello D, 1995, Report on intensive treatment of extracapillary glomerulonephritis with focus on cresentic IgA nephropathy, Nephrol Dial Transplant, 10, 2054

Simon P, 1983, Disappearance of the mesangial IgA in IgA nephropathies after plasma‐exchanges (PE), Eur J Clin Invest, 13, A45

10.1002/jca.2920030308

Dau PC, 1981, Plasmapheresis in idiopathic inflammatory myopathy, Experience with 35 patients. Arch Neurol, 38, 544

Steven A, 2011, Inclusion body myositis, . Opin Rheumatol, 23, 574, 10.1097/BOR.0b013e32834b53cc

10.1002/ibd.20833

10.1111/j.1440-1746.2008.05595.x

10.1016/j.dld.2007.01.001

10.1111/j.1365-2036.2010.04295.x

10.1007/s10620-006-9696-x

10.1016/j.dld.2008.01.007

10.1159/000080079

10.1016/j.dld.2008.11.020

10.1111/j.1442-200X.2007.02392.x

10.1002/ibd.20505

10.1111/j.1744-9987.2008.00639.x

10.1007/s00384-011-1193-9

10.1002/jca.21202

10.1111/j.1744-9987.2011.00970.x

10.1002/jca.20315

10.1097/01.MIB.0000195386.19268.b3

10.1002/ibd.23012

10.3748/wjg.v13.i15.2193

10.1097/MEG.0b013e3282f5e9a4

10.1007/s00535-007-2129-6

10.1038/ajg.2009.453

10.1007/s10620-005-9012-1

10.1111/j.1440-1746.2010.06377.x

10.1097/01.MIB.0000195387.26892.22

10.1053/j.gastro.2008.04.023

10.1046/j.1526-0968.2003.00012.x

10.2174/1381612033391928

10.1002/jca.1000

10.1111/j.1365-2036.2010.04490.x

10.1111/j.1365-2036.2004.02189.x

10.3748/wjg.v12.i4.520

10.1007/s00535-011-0464-0

10.1212/WNL.47.3.678

10.1002/ana.410110604

10.1002/jca.21219

Jost WH, 1991, Therapeutic approaches to Lambert‐Eaton myasthenic syndrome in the intra‐individual comparison, Wien Klin Wochenschr, 103, 629

Keogh M, 2011, Treatment for Lambert‐Eaton myasthenic syndrome, Cochrane Database Syst Rev, CD003279

10.1136/jnnp.43.6.483

Lambert EH, 1956, Defect of neuromuscular conduction associated with malignant neoplasms, Am J Physiol, 187, 612

10.1056/NEJM199506013322203

10.1056/NEJM198912073212303

10.1111/j.1749-6632.1998.tb11023.x

10.1212/WNL.34.4.480

Newsom‐Davis J, 1982, Lambert‐Eaton myasthenic syndrome: electro‐ physiological evidence for a humoral factor, Muscle Nerve, 5, S17

10.1111/j.1749-6632.1998.tb11024.x

10.1016/S1474-4422(11)70245-9

10.1038/clpt.2009.35

10.1177/039139889501800507

10.1002/(SICI)1098-1101(1996)11:2<78::AID-JCA4>3.0.CO;2-7

Bambauer R, 1995, LDL‐apheresis in treatmet of two patients with heterozygous familial hypercholesterolemia and extremely elevated lipoprotein(a) levels, Transfus Sci, 16, 375

10.1016/j.transci.2011.11.016

10.1016/j.jacl.2011.11.003

10.1038/ncpcardio1456

10.1016/S1567-5688(09)71818-5

10.1111/j.1744-9987.2007.00449.x

10.1093/eurheartj/ehq386

10.1016/0009-3084(94)90153-8

10.1016/j.transci.2009.10.003

10.1111/j.1744-9987.1998.tb00112.x

10.1016/S1567-5688(09)71817-3

10.1016/S0955-3886(96)90086-7

10.1155/2008/715769

10.1111/j.1399-0012.2005.00470.x

10.1002/lt.500060122

10.1002/hep.21928

10.1053/jlts.2000.6448

10.1097/00007890-199504270-00009

Gelas T, 2011, ABO‐incompatible pediatric liver transplantation in very small recipients: Birmingham's experience, Pediatr Transplant, 15:706

10.1002/lt.20652

Available at:http://optn.transplant.hrsa.gov: Accessed February 12 2013.

10.1097/TP.0b013e318173a70e

10.1016/j.transproceed.2008.03.174

10.1097/TP.0b013e31825c591e

10.1002/jca.21244

10.1097/00007890-199504150-00011

10.1097/01.TP.0000137264.99113.2B

10.1016/j.transproceed.2012.01.029

10.1097/TP.0b013e318239e8e4

10.1046/j.1365-3148.2001.00313.x

10.1111/j.1399-3089.2006.00286.x

10.1111/j.1365-2362.2010.02339.x

10.1002/lt.20727

10.1111/j.1432-2277.2003.tb00303.x

Yagci G, 2005, Successful ABO‐incompatible liver transplantation with pre‐ and postoperative plasmapheresis, triple immunosuppression, and splenectomy for fulminant hepatic failure, Exp Clin Transplant, 3, 390

10.1016/j.healun.2005.05.015

10.1007/s10227-003-5005-x

Badesch DB, 1998, Pulmonary capillaritis: a possible histologic form of acute pulmonary allograft rejection, J Heart Lung Transplant, 17, 415

10.1097/TP.0b013e31818bc024

10.1016/j.healun.2012.11.005

10.1097/00007890-200103150-00012

10.1016/j.healun.2009.08.004

10.1016/j.healun.2010.01.012

10.1097/MOT.0b013e32832fb981

10.1016/j.healun.2012.05.002

10.1002/jca.10009

10.1016/j.ejcts.2009.02.035

10.1097/01.TP.0000157278.02848.C7

10.1097/00007890-200211150-00013

10.1002/jca.20274

10.1002/jca.20089

10.1016/j.healun.2004.11.068

10.1016/j.transproceed.2006.10.227

10.1016/j.healun.2009.08.029

10.1016/j.healun.2008.09.013

10.1378/chest.115.5.1459

Organ procurement and transplantation network (OPTN)/Scientific registry of transplant recipients (SRTR)2010Annual Report. Available at:http://www.srtr.org/annual_reports/2010/1204_rec‐tx‐proc‐ty_lu.htm

10.1016/S0022-5223(99)70241-2

10.1345/aph.1Q509

Villanueva J, 2000, Extracorporeal photopheresis for the treatment of lung allograft rejection, Ann Transplant, 5, 44

Achavanuntakul B, 2001, Exchange transfusion in severe falciparum malaria: a simple method modified from hemodialysis circuit, J Med Assoc Thai, 84, 314

10.1186/1475-2875-11-158

10.1542/peds.2005-0314

10.1111/j.1744-9987.2009.00754.x

Deshpande A, 2003, Red cell exchange using cell separator (therapeutic erythrocytapheresis) in two children with acute severe malaria, J Assoc Physicians India, 51, 925

10.7326/0003-4819-100-3-396

10.1056/NEJMcpc069022

10.1016/j.jemermed.2012.02.051

10.1111/j.1445-5994.2010.02362.x

10.1016/S0035-9203(00)90101-9

10.1016/S0163-4453(99)90055-5

Molla S, 2001, Role of exchange transfusion in patients with severe Falciparum malaria: report of six cases, Haematologica, 86, 208

10.1016/j.actatropica.2006.05.003

10.1111/j.1537-2995.2009.02530.x

10.3233/CH-2010-1354

Sighinolfi L, 1990, Treatment of cerebral malaria by erythrocyte exchange, Recenti Prog Med, 81, 804

10.1097/00000441-200011000-00008

10.1002/jca.20309

10.1046/j.1537-2995.2000.40060702.x

10.1002/jca.1002

10.1007/s15010-001-1040-y

10.1046/j.1365-3156.1997.d01-375.x

Chuncharunee S, 1997, Levels of serum tumor necrosis factor alpha in relation to clinical involvement and treatment among Thai adults with Plasmodium falciparum malaria, J Med Assoc Thai, 80, S72

Gulprasutdilog S, 1999, Exchange transfusion in severe falciparum malaria, J Med Assoc Thai, 82, 1

10.1111/j.1365-3156.1998.00198.x

10.1179/000349803225001364

10.1007/s00134-003-1982-x

10.1016/j.jinf.2006.12.003

Looareesuwan S, 1990, Plasmodium falciparum hyperparasitaemia: use of exchange transfusion in seven patients and a review of the literature, Q J Med, 75, 471

10.1097/00006454-199408000-00006

10.1056/NEJM198907133210201

Pinanong M, 1997, Exchange transfusion therapy in severe complicated malaria, J Med Assoc Thai, 80, 332

10.1053/tmrv.2002.33437

10.1086/339810

10.1007/BF01690765

Srichaikul T, 1993, Exchange transfusion therapy in severe complicated malaria, Southeast Asian J Trop Med Public Health, 24, 100

Ende J, 1994, Twelve patients with severe malaria treated with partial exchange transfusion. Comparison between mathematically predicted and observed effect on parasitaemia, Trop Geogr Med, 46, 340

10.1111/j.1537-2995.2009.02488.x

Available at:http://www.cdc.gov/malaria/diagnosis_treatment/index.html; Accessed on March 15 2013.

Available at:http://www.who.int/malaria/publications/atoz/9789241547925/en/index.html; Accessed on March 15 2013.

10.1007/s00415-004-0588-8

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis, 1991, The Canadian Cooperative Multiple Sclerosis Study Group, Lancet, 337, 441, 10.1016/0140-6736(91)93389-Q

10.1016/S1474-4422(10)70028-4

10.1093/brain/aws105

10.1056/NEJM198301273080401

10.1016/S0140-6736(05)67102-4

Khatri BO, 2009, Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function, Neurology, 72, 401, 10.1212/01.wnl.0000341766.59028.9d

10.1212/WNL.35.3.312

10.1212/WNL.41.3.409

10.1212/WNL.0b013e3181b879be

10.1016/j.ncl.2004.09.002

10.1001/archneurol.2011.34

Meca‐Lallana JE, 2003, Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study, Revista de Neurol, 37, 917

10.1111/j.1365-2362.2005.01518.x

10.1056/NEJM200009283431307

10.1146/annurev-med-042910-135833

10.1212/01.WNL.0000138437.99046.6B

10.1001/archneurol.2010.157

10.1212/WNL.32.7.739

10.1159/000332397

10.1002/jca.2920100402

10.1212/WNL.39.9.1143

10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q

10.1212/WNL.0b013e31821e5505

10.1016/j.ejcts.2008.11.006

10.1002/ana.410410615

Gajdos P, 2002, Plasma exchange for myasthenia gravis, Cochrane Database Syst Rev, CD002275

Gajdos P, 2008, Intravenous immunoglobulin for myasthenia gravis, Cochrane Database Syst Rev, 10.1002/14651858.CD002277.pub3

Gajdos P, 1983, Long‐term effects of plasma exchange in myasthenia. Results of a randomized study, Presse Med, 12, 939

10.1111/j.1749-6632.1987.tb51406.x

10.1002/jca.20317

10.1002/ana.22139

10.1046/j.1525-1594.2001.06717.x

10.1510/icvts.2007.170894

10.1007/s00415-006-0235-7

10.1111/j.1600-0404.1999.tb07336.x

10.1007/s004150070149

10.1007/s11255-007-9230-x

10.1111/j.1537-2995.2006.01143.x

10.7326/0003-4819-143-11-200512060-00005

10.1038/sj.thj.6200312

10.1111/j.1744-9987.2005.00322.x

10.1136/bmj.1.6008.503

Goel SK, 2011, El‐Ghoroury M. Myeloma cast nephropathy: a rare cause of primary renal allograft dysfunction.Transplant Proc, 2784

10.1002/(SICI)1098-1101(2000)15:1/2<28::AID-JCA4>3.0.CO;2-N

Gupta D, 2010, Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int, 14, 355

Hay SN, 2002, Plasma exchange for rapidly progressive myeloma kidney, Abstract. J Clin Apher, 17, 142

10.1681/ASN.2010080857

Johnson WJ, 1990, Treatment of renal failure associated with multiple myeloma, Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med, 150, 863

Knudsen LM, 2000, Renal failure in multiple myeloma: reversibility and impact on the prognosis, Nordic Myeloma Study Group. Eur J Haematol, 65, 175, 10.1034/j.1600-0609.2000.90221.x

Locatelli F, 1980, Steroid pulses and plasmapheresis in the treatment of acute renal failure in multiple myeloma, Proc Eur Dial Transplant Assoc, 17, 690

10.1016/0002-9343(79)91185-9

10.1016/S0272-6386(87)80007-0

10.1159/000013424

Pasquali S, 1985, Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma, Int J Artif Organs, 8, 27

Paul M, 1982, Plasmapheresis therapy in a patient with multiple myeloma, Can Med Assoc J, 127, 956

10.1038/ki.2008.138

Raje NS, 2011, Case records of the Massachusetts General Hospital: Case 29 −2011: a 66‐year‐old woman with cardiac and renal failure, N Engl J Med., 22, 1129, 10.1056/NEJMcpc1100925

10.1038/ki.1988.127

Zucchelli P, 1984, Plasma exchange therapy in acute renal failure due to light chain myeloma, Trans Am Soc Artif Intern Organs, 30, 36

10.1097/BOR.0b013e328333bf3d

10.1097/00000372-200306000-00004

10.1111/j.1365-2133.2005.06434.x

10.1016/j.jaad.2010.08.041

10.1097/00003072-200411000-00004

Hofmann JC, 2005, Nephrogenic fibrosing dermopathy: response to plasma exchange, J Clin Apher, 20, 12

10.1046/j.1365-2133.2003.05181.x

10.1159/000077321

10.1067/mjd.2003.78

10.1111/j.1600-6143.2006.01420.x

10.1002/jca.20170

Pesek GD, 2006, Extracorporeal photopheresis (ECP), a promising treatment for nephrogenic fibrosing dermopathy (NFD), J Clin Apher, 21, 13

10.1001/archderm.143.8.1025

10.1016/j.jaad.2009.03.040

10.1177/039139880803101009

10.1016/j.jcmg.2011.08.013

Available at:http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm124344.htm; Accessed on September 3 2012.

10.1111/j.1600-0404.2008.01002.x

10.2174/157015911796557948

Bonnan M, 2011, Plasma exchange in severe attacks of neuromyelitis optica, Mult Scler Int, 2012, 1155

10.1177/1352458508100837

10.1212/WNL.58.1.143

10.1002/jca.21215

10.1590/S0004-282X2008000100034

10.1212/WNL.0b013e3181b879be

10.1001/archophthalmol.2012.1126

10.1111/j.1744-9987.2009.00780.x

10.1016/j.jocn.2010.07.141

10.1212/01.WNL.0000138437.99046.6B

10.1212/WNL.0b013e31823dc535

10.1002/ana.22657

10.1016/j.jocn.2010.05.030

10.1177/1352458506071174

10.1007/s11940-008-0007-z

10.1089/jop.2009.0150

10.1212/WNL.0b013e318207b1f6

10.3109/00313020903493955

10.1592/phco.27.11.1529

10.1016/j.toxicon.2008.10.013

10.1212/01.wnl.0000341766.59028.9d

10.1016/0041-0101(90)90163-2

10.1056/NEJMoa0810316

10.1007/s00467-011-1985-8

10.1016/j.annfar.2009.01.011

10.1093/ndt/gfg1049

10.1002/jca.20097

Rasulov AR, 1994, [Intensive therapy in bites of poisonous snakes], Anesteziol Reanimatol, 59

Rubik J, 2003, Clinical aspects of plasmapheresis therapy in children: single center experience, Pol Merkuriusz Lek, 14, 304

10.1016/j.transci.2011.07.015

10.1001/archneur.64.2.169

Szczepiorkowski ZM, 2003, Apheresis: Principles and Practice, 375

10.1002/jca.20094

10.1056/NEJMra1114525

Valavi E, 2011, ADAMTS‐13 deficiency following Hemiscorpius lepturus scorpion sting, Saudi J Kidney Dis Transplant, 22, 792

10.1056/NEJMoa0810257

10.1002/(SICI)1098-1101(2000)15:1/2<53::AID-JCA5>3.0.CO;2-W

10.1136/adc.2009.164889

10.1111/j.1749-6632.1988.tb27127.x

10.1212/WNL.38.9.1391

10.1016/j.pediatrneurol.2005.05.018

10.1023/A:1006136219490

Bloch MH, 2004, Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome, Obstet Gynecol, 104, 1174, 10.1097/01.AOG.0000128110.31784.c8

10.1002/1097-0142(19950401)75:7<1678::AID-CNCR2820750719>3.0.CO;2-2

10.1056/NEJMra023009

Dalmau J, 1992, Anti‐Hu–associated paraneoplastic encephalomyelitis/sensory neuronopathy, A clinical study of 71 patients. Medicine, 71, 59

10.1212/WNL.44.12.2241

Dalmau JO, 1997, Paraneoplastic syndromes affecting the nervous system, Semin Oncol, 24, 318

10.1002/(SICI)1097-0142(19961115)78:10<2153::AID-CNCR16>3.0.CO;2-Y

10.1002/ana.410370711

10.1212/WNL.40.7.1085

10.1212/WNL.40.10.1621

10.1097/WCO.0b013e328359da15

Graus F, 2007, Paraneoplastic neurological syndromes: diagnosis and treatment, Curr Opin Neurol, 20, 732

10.1212/WNL.42.3.536

10.1002/ana.410190117

10.1212/WNL.42.10.1938

10.1016/S0022-510X(00)00407-X

10.1016/S0889-8588(05)70375-0

10.1080/15622970701459802

10.1111/j.1744-9987.2007.00546.x

10.1212/WNL.44.12.2412

10.1093/brain/116.2.453

Mani R SS, 2004, Opsoclonus myoclonus syndrome: response to plasmapheresis, Indian Pediatr, 41, 499

10.1212/WNL.55.5.713

10.4065/75.12.1321

10.1136/adc.2008.149021

10.1093/brain/awg133

10.1007/s00415-002-0706-4

10.1111/j.1744-9987.2006.00348.x

10.1136/jnnp.60.4.388

10.1007/s004150050419

10.1111/j.1468-1331.2006.01266.x

10.1215/S1152851703000395

10.1002/jca.2920050104

10.1016/S0887-8994(00)00227-7

Lunn MP, 2012, Immunopathy for IgM anti‐myelin‐associated glycoprotein paraprotein‐associated peripheral neuropathies, Cochrane Database Syst Rev, 5, CD002827

10.1111/j.1468-1331.2011.03380.x

10.1007/s11910-011-0237-4

Guidelines for the diagnosis of rheumatic fever, 1992, Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association, JAMA, 268, 2069

Arnold PD, 2001, Is obsessive‐compulsive disorder an autoimmune disease?, Cmaj, 165, 1353

10.1016/S1474-4422(06)70494-X

10.1097/01.chi.0000179056.54419.5e

10.1542/peds.2007-1307

Gajdos P, 2003, Intravenous immunoglobulin for myasthenia gravis, Cochrane Database Syst Rev, CD002277

10.1177/08830738050200050601

10.1097/00004583-199607000-00017

10.1016/S0165-5876(03)00158-7

10.1111/j.1469-8749.2003.tb00402.x

Lopez Y, 2007, Therapeutic plasma exchange (TPE) in a patient with pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS), J Clin Apher, 22, 82

10.1001/archpedi.156.4.356

10.1016/S0140-6736(98)12297-3

10.1111/j.1460-9592.2005.01768.x

Sasson Y, 1997, Epidemiology of obsessive‐compulsive disorder: a world view, J Clin Psychiatry, 58, 7

10.1016/j.biopsych.2004.12.035

10.1542/peds.2004-0308

10.1542/peds.110.2.331

10.1038/sj.mp.4001542

10.4172/2161-0665.1000113

10.1176/ajp.155.2.264

10.1016/j.parkreldis.2005.02.007

10.1016/j.ejpn.2004.03.005

10.1038/mp.2009.77

10.1001/archderm.1979.04010060036025

10.1001/archderm.1988.01670110019004

10.1111/j.1365-2133.1979.tb05571.x

10.1001/archderm.1983.01650270033013

10.1159/000249707

10.1111/j.1346-8138.2001.tb00054.x

10.1067/mjd.2000.109297

10.1016/S0190-9622(08)80854-7

10.1159/000018090

10.1111/j.1749-6632.2009.04737.x

Martin LK, 2009, Interventions for pemphigus vulgaris and pemphigus foliaceus, Cochrane Database Syst Rev (Online), CD006263

10.1016/j.clindermatol.2011.03.014

10.1007/s00403-009-1024-9

10.1016/j.transci.2010.10.006

10.1111/j.1744-9987.2007.00497.x

10.1046/j.1526-0968.2003.00077.x

10.1097/00001721-199909000-00004

10.1002/jca.10055

10.1002/jca.20033

10.1111/j.1744-9987.1997.tb00055.x

10.1111/j.1744-9987.1997.tb00045.x

10.1177/039139889702000310

10.7326/0003-4819-125-12-199612150-00001

10.1159/000108634

10.1016/S1078-5884(11)60014-2

Tsuchida H, 2006, Effect of low‐density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P‐LAS), Int Angiol, 25, 287

10.1161/ATVBAHA.109.200212

10.1111/j.1525-139X.2011.01036.x

Dick JPR, 1993, Hypokalemia in acute Refsum's disease, J R Soc Med, 86, 171, 10.1177/014107689308600319

10.1111/j.1469-8749.1989.tb08416.x

10.1016/S0140-6736(79)91005-5

10.1111/j.1600-0404.1985.tb01541.x

10.1016/0955-3886(93)90049-Z

10.1111/j.1600-0404.1996.tb07051.x

10.1136/jnnp.54.7.614

10.1159/000115788

10.1007/BF02191145

10.1136/jnnp.62.6.671-a

10.1159/000114592

Moser HW, 1980, Therapeutic trial of plasmapheresis in Refsum disease and in Fabry disease, Birth Defects Orig Artic Ser, 16, 491

10.1016/0002-9343(81)90889-5

Penovich PE, 1978, Advances in Neurology, 151

Siegmund JB, 1995, Cascade filtration in Refsum's disease, Nephrol Dial Transplant, 10, 117

10.1007/BF02435981

10.1016/S1473-0502(03)00102-2

10.1007/s00018-005-5463-y

10.1002/(SICI)1098-1101(1999)14:4<181::AID-JCA5>3.0.CO;2-Z

10.1093/qjmed/94.8.403

10.1002/jca.21200

Blaha M, 2002, The role of erythrocytapheresis in secondary erythrocytosis therapy, Clin Hemorheol Microcirc, 26, 273

10.1016/j.transci.2012.07.017

10.1002/jca.21241

Elliott MA, 2004, Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera, Curr Hematol Rep, 3, 344

10.1007/BF01648884

10.1111/j.1744-9987.1997.tb00028.x

10.1111/j.1365-2141.2005.05535.x

Pollari G, 1999, The role of erythrocytapheresis in secondary erythrocytosis therapy, Clin Hemorheol Microcirc, 21, 353

10.3109/09537104.2011.633178

10.1056/NEJMra035363

10.1179/102453310X12719010991740

10.1002/ajh.23135

10.1007/s12032-007-9008-0

10.1016/S0955-3886(00)00042-4

Vecchio S, 2007, A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocytapheresis in patients with erythrocytosis, Blood Transfus, 5, 20

10.1055/s-2003-44560

10.1007/BF01737944

Ako S, 1999, Crow‐Fukase syndrome‐ immunoadsorption plasmapheresis effectively lowers elevated interleukin‐6 concentration, Nephrol Dial Transplant, 14, 419, 10.1093/ndt/14.2.419

Atsumi T, 1995, A case of Crow‐Fukase syndrome with elevated soluble interleukin‐6 receptor in cerebrospinal fluid. Response to double‐filtration plasmapheresis and corticosteroids, Acta Haematol, 93, 90, 10.1159/000203980

10.1002/ajh.23288

10.1007/s11864-004-0016-4

10.1111/j.1600-0609.2008.01037.x

10.1182/blood-2002-07-2299

10.1002/jca.2920020309

10.1016/0002-9343(94)90350-6

Arnold DM, Rossi's Principles of Transfusion Medicine, 344

10.1111/j.1365-2141.1985.tb02876.x

Bussel J, 2008, Hematology: Basic Principles and Practice, 2083

10.1002/ajh.20093

10.1016/S1473-0502(03)00049-1

10.1097/00043426-200312001-00009

10.1016/S0190-9622(83)70022-8

10.1007/BF00455159

10.1159/000014311

10.1001/archderm.115.10.1171

10.1016/j.jaad.2012.09.037

10.1111/j.1744-9987.2012.01109.x

10.1111/j.1744-9987.2012.01108.x

10.1111/j.1744-9987.2006.00369.x

10.1016/S0190-9622(03)02474-5

10.1067/S0190-9622(03)00795-3

10.1002/jca.20079

10.1007/BF00412488

Molochkov VA, 2012, Clinical and immunological aspects of extracorporeal photochemotherapy for psoriasis and psoriatic arthritis, Ter Arkh, 84, 69

10.1002/art.1780390911

10.1016/0190-9622(90)70278-P

10.1111/j.1365-2133.1990.tb08269.x

10.1111/j.1365-2141.1980.tb07185.x

10.1016/S0140-6736(76)92906-8

10.1136/bmj.1.6070.1185

10.1080/00016340802268880

Kirsten GF, 1995, The outcome of babies of mothers with severe rhesus incompatibility treated at Tygerberg Hospital, 1980–1993, S Afr Med J, 85, 1091

10.1016/j.ajog.2006.10.890

10.1515/jpme.1997.25.1.85

10.1111/j.1432-2277.2011.01309.x

10.1681/ASN.2009101065

10.1111/j.1600-6143.2009.02591.x

10.1056/NEJMoa1012376

10.1097/TP.0b013e3181a76ae1

10.1111/j.1600-6143.2005.01178.x

10.1056/NEJMoa0707894

AuBuchon JP, 2008, Reducing the variation in performance of antibody titrations, Archives Pathol Lab Med, 132, 1194, 10.5858/2008-132-1194-RTVIPO

10.1111/j.1600-6143.2007.01750.x

10.1097/00007890-200103150-00013

10.1111/j.1399-3089.2006.00293.x

10.1097/TP.0b013e31820f08e8

10.2215/CJN.02940311

10.1034/j.1600-6143.2002.020101.x

Available at:http://optn.transplant.hrsa.gov; Accessed on February 12th 2013.

10.1111/j.1600-6143.2008.02451.x

10.1111/j.1600-6143.2009.03001.x

10.1097/TP.0b013e3181dc734f

10.1097/TP.0b013e3181a76ae1

10.1002/jca.20206

10.1111/j.1600-6143.2010.03103.x

10.1111/j.1537-2995.2008.02085.x

10.1111/j.1600-6143.2004.00653.x

10.1002/jca.20002

10.1111/j.1432-2277.2003.tb00303.x

10.1111/j.1525-1594.1983.tb04203.x

Schultz SH, 2007, Schizophrenia: a review, Am Fam Physician, 75, 1821

10.1016/S1473-0502(01)00078-7

10.1002/art.1780240903

10.1016/S0190-9622(99)70246-X

10.1016/j.jaad.2005.11.1091

10.1002/jca.2920010404

10.1111/j.1365-2133.2005.06857.x

10.1097/BOR.0b013e328337c3d6

10.1016/j.clim.2011.09.014

10.1001/archderm.1992.01680130051005

10.1007/s10067-008-1062-2

10.1016/j.disamonth.2003.12.003

10.1136/bmj.288.6415.439

Brandtzaeg P, 1985, Plasmapheresis in the treatment of severe meningococcal or pneumococcal septicaemia with DIC and fibrinolysis. Preliminary data on eight patients, Scand J Clin Lab Invest Suppl, 178, 53

10.1007/s00134-002-1410-7

10.1002/jca.2920100403

10.1186/cc11256

10.1097/00006454-198906000-00015

10.1159/000314864

10.1016/j.transci.2012.07.011

10.1046/j.1526-0968.2002.00449.x

Kumar A, 1998, Plasma exchange and haemodiafiltration in fulminant meningococcal sepsis, Nephrol Dial Transplant, 13, 484, 10.1093/oxfordjournals.ndt.a027853

10.1097/00130478-200301000-00002

10.1016/S1473-0502(03)00100-9

10.1046/j.1526-0968.2001.005002123.x

10.1111/j.1525-139X.2011.01029.x

10.1007/s001340051200

10.1007/BF01712247

10.1097/00130478-200007000-00016

10.1097/CCM.0b013e318186aa49

10.1159/000319702

10.1002/jca.20296

10.1097/00003246-199910000-00003

10.1056/NEJM197905313002220

10.1007/BF03010573

10.1097/01.CCM.0000064742.00981.14

10.1016/0002-9343(92)90761-Y

10.1093/clind/15.3.424

10.1111/j.1744-9987.2009.00714.x

10.1056/NEJM199807023390102

10.1002/pbc.20317

10.1111/j.1365-2141.2011.08999.x

10.1136/bmj.327.7424.1151

10.1046/j.1526-0968.2002.00396.x

10.1002/ajh.20685

10.1016/S0037-1963(01)90057-5

10.1016/j.ijgo.2006.09.017

10.1016/j.jpeds.2006.06.037

Kalff A., 2011, The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults, Br J Haematol, 154, 656

10.1136/jcp.40.5.505

10.1182/blood.V83.4.1136.1136

10.1002/(SICI)1098-1101(2000)15:1/2<129::AID-JCA7>3.0.CO;2-H

10.1002/jca.21203

Ohene‐Frempong K, 2001, Indications for red cell transfusion in sickle cell disease, Semin Hematol, 38, 5, 10.1053/shem.2001.20139

10.1097/00043426-198507030-00019

10.1182/blood.V76.7.1431.1431

10.1080/02724936.1989.11748610

10.1002/jca.20294

Shao SH, 1995, Sickle cell intrahepatic cholestasis: approach to a difficult problem, Am J Gastroenterol, 90, 2048

10.1002/pbc.24179

10.1007/BF02029357

10.1002/pbc.24178

10.1097/MPH.0b013e318190d707

10.1182/asheducation-2006.1.48

Thurston GB, 2004, Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood, Clin Hemorheol Microcirc, 30, 83

10.1111/j.1537-2995.2008.02075.x

10.1002/pbc.22211

10.1056/NEJM200006223422502

10.1002/pbc.23145

10.1182/blood-2011-11-327361

10.1056/NEJM199807023390102

10.1002/pbc.20317

Al‐Samak ZM, 2008, Assessment of perioperative transfusion therapy and complications in sickle cell disease patients undergoing surgery, Middle East J Anesthesiol, 19, 983

10.1136/bmj.327.7424.1151

Cohen AR, 1992, A modified transfusion program for prevention of stroke in sickle cell disease, Blood, 7, 1657, 10.1182/blood.V79.7.1657.1657

10.1046/j.1526-0968.2002.00396.x

10.1002/ajh.20685

10.1016/S0037-1963(01)90057-5

10.1002/(SICI)1098-1101(2000)15:1/2<129::AID-JCA7>3.0.CO;2-H

10.1016/j.ijgo.2006.09.017

Haberkern CM, 1997, Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group, Blood, 89, 1533

10.1001/archotol.1997.01900070033005

10.1016/S0140-6736(12)61726-7

10.1016/j.jpeds.2006.06.037

Kalff A., 2011, The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults, Br J Haematol, 154, 656

10.1136/jcp.40.5.505

10.1182/blood.V83.4.1136.1136

10.1182/blood.V86.10.3676.bloodjournal86103676

10.1002/jca.21203

10.1067/mpd.2001.119593

Navaid M., A palliative care approach in treating patients with sickle cell disease using exchange transfusion, Am J Hosp Palliat Care, 27, 215, 10.1177/1049909109356966

Ohene‐Frempong K, 2001, Indications for red cell transfusion in sickle cell disease, Semin Hematol, 38, 5, 10.1053/shem.2001.20139

Plah OS, 1991, Pain in sickle cell disease, rates and risk factors, NEJM, 325, 11, 10.1056/NEJM199107043250103

10.1182/blood.V76.7.1431.1431

10.1002/jca.20294

10.1002/(SICI)1098-1101(1999)14:3<122::AID-JCA3>3.0.CO;2-A

10.1097/MPH.0b013e318190d707

10.1002/pbc.22211

10.1002/(SICI)1096-8652(199911)62:3<129::AID-AJH1>3.0.CO;2-J

10.1056/NEJM200006223422502

10.1016/j.jpeds.2005.02.030

10.1002/pbc.23145

10.1182/blood-2011-11-327361

Vichinsky EP, 1995, A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease, NEJM, 333:206

10.1161/CIRCULATIONAHA.109.882464

10.1136/jnnp.65.5.633

10.1212/WNL.41.10.1588

10.1016/S0025-6196(12)61012-X

10.1056/NEJMoa01167

10.1055/s-2008-1041073

10.2169/internalmedicine.49.2821

10.1001/archneurol.2011.991

10.1002/mus.23234

10.1212/01.WNL.0000073143.53337.DD

Alpa M, 2011, Apheresis as a rescue therapy in a severe case of sudden hearing loss, Int J Artif Organs, 34, 589, 10.5301/IJAO.2011.8548

10.1111/j.1744-9987.2005.00316.x

10.1002/lary.20835

10.1002/jca.20081

10.1016/j.autrev.2011.05.005

10.1016/S1567-5688(09)71820-3

10.1016/S1567-5688(09)71821-5

Luetje CM, 1997, Plasmapheresis in autoimmune inner ear disease: long‐term follow‐up, Am J Otol, 18, 572

10.1097/MAO.0b013e31817e5d03

10.1007/s00405-008-0823-5

10.1111/j.1744-9987.2006.00380.x

10.1046/j.1526-0968.2001.00369.x

10.1016/S0140-6736(02)11768-5

10.1007/PL00007510

10.1097/00129492-200205000-00013

10.1080/00016489950180397

10.1002/jca.20001

10.1007/s00106-009-2004-2

10.1016/j.berh.2005.05.006

10.1046/j.1525-1594.2000.06623.x

10.1016/j.clinthera.2012.02.028

10.1007/s10067-007-0576-3

10.1002/jca.10020

10.1016/j.transci.2010.10.003

10.1155/2012/380391

10.1016/S0140-6736(83)91561-1

10.1046/j.1526-0968.2003.00040.x

10.1006/jaut.1998.0229

10.1177/096120339500400607

10.1007/s00296-005-0031-1

10.1002/jca.2920070314

10.1056/NEJM199205213262101

10.1046/j.1526-0968.2003.00032.x

10.1007/s001050050775

10.1007/978-1-4684-5718-6_21

10.1002/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1

10.4049/jimmunol.0901773

10.1002/jca.20028

Adami R, 1993, Therapeutic thrombocytapheresis: a review of 132 patients, Int J Artif Organs, 16, 183, 10.1177/039139889301605s40

10.1002/1097-0142(19930815)72:4<1209::AID-CNCR2820720413>3.0.CO;2-4

Beard ME, 1980, Control of thrombocytosis by plateletpheresis using a cell separator, N Z Med J, 91, 136

10.1182/blood.V64.5.981.981

10.1055/s-2007-996119

10.1182/blood-2012-04-424911

10.1016/j.athoracsur.2011.02.050

10.1016/j.ajem.2007.09.025

10.1111/j.1365-2141.2004.05277.x

10.1046/j.1526-0968.2002.00394.x

Koh LP, 2002, Four pregnancies in two patients with essential thrombocythaemia‐a case report, Ann Acad Med Singapore, 31, 353

10.1002/cncr.22021

10.1007/s11239-006-9016-5

10.1046/j.1537-2995.1980.20581034507.x

10.1182/blood.V50.5.927.927

10.1046/j.1365-2141.1997.4823285.x

10.1034/j.1600-0609.2001.00367.x

10.1002/jca.20101

10.1016/j.transci.2005.12.002

10.1136/hrt.2004.039214

Au WY, 2000, Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin, Haematologica, 85, 659

10.1097/00000441-200312000-00015

10.1056/NEJM200006153422402

10.1016/j.jacc.2007.04.093

10.1158/1078-0432.CCR-11-0804

Boctor FN, 2006, Tacrolimus (FK506) associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in lung transplant salvage with a plasmapheresis and cyclosporin, Egypt J Immunol, 13, 95

10.1093/jnci/89.24.1895

10.1016/S0041-1345(97)01452-8

10.1007/s00296-008-0826-y

10.1097/00007611-200007000-00020

10.1046/j.1365-2141.2001.02795.x

10.1001/jama.289.22.2947

10.1056/NEJMoa0707330

10.1002/(SICI)1097-0142(19990501)85:9<2023::AID-CNCR21>3.0.CO;2-2

10.1002/(SICI)1098-1101(1998)13:3<120::AID-JCA5>3.0.CO;2-E

10.1002/jca.20213

10.1097/00007890-199301000-00039

10.1002/cncr.20290

10.1007/s10147-007-0676-8

10.1055/s-0032-1328886

10.1016/S0272-6386(99)70194-0

10.1016/S0272-6386(99)70269-6

10.1002/ajh.2830470407

10.1002/ajh.20440

10.1159/000168444

10.5414/CNP59148

10.7326/0003-4819-135-12-200112180-00008

10.1016/j.ygyno.2004.12.027

10.1159/000013525

10.1111/j.1445-5994.2006.01104.x

10.1097/00062752-200109000-00004

10.1007/s00277-004-0938-8

10.1002/(SICI)1096-8652(199608)52:4<310::AID-AJH11>3.0.CO;2-H

10.1592/phco.24.6.664.34732

McDonald SP, 1997, Quinine‐induced hemolytic uremic syndrome, Clin Nephrol, 47, 397

10.5694/j.1326-5377.2002.tb04440.x

10.1016/j.lts.2003.09.021

10.1097/00132580-200107000-00003

10.1002/jca.20194

Patel TN, 2006, Use of ticlopidine and cilostazol after intracoronary drug‐eluting stent placement in a patient with previous clopidogrel‐induced thrombotic thrombocytopenic purpura: a case report, J Invasive Cardiol, 18, E211

10.1053/j.ajkd.2010.11.030

10.1200/JCO.2003.03.111

10.1016/S0041-1345(98)00338-8

10.1046/j.1523-1755.2001.060003831.x

Sabto JK, 1981, Hemodialysis, peritoneal dialysis, plasmapheresis and forced diuresis for the treatment of quinine overdose, Clin Nephrol, 16, 264

Saif MW, 2005, Hemolytic‐uremic syndrome associated with gemcitabine: a case report and review of literature, JOP, 6, 369

10.1046/j.1537-2995.2003.00282.x

10.1038/sj.bjc.6690242

10.1097/00007890-199902270-00009

10.1159/000067270

10.1053/ajkd.2002.35758

10.1081/JDI-100108197

10.1038/ki.2008.613

10.1161/01.STR.0000109253.66918.5E

10.1038/ki.2008.613

10.1046/j.1523-1755.1999.00492.x

10.1016/S1470-2045(07)70203-6

10.1038/sj.bmt.1705758

10.1097/TP.0b013e3181f24e8d

10.1038/sj.bmt.1705976

10.2165/00003495-200969020-00004

10.1046/j.1526-0968.2003.00026.x

10.1038/sj.bmt.1703710

10.4065/78.4.421

10.1111/j.1537-2995.2004.00700.x

10.1053/j.seminhematol.2003.10.001

10.1016/j.bbmt.2005.06.001

10.1038/bmt.2009.233

10.1111/j.1537-2995.2009.02217.x

10.1182/blood-2011-02-321315

10.1016/j.bbmt.2006.11.020

10.3324/haematol.10699

10.1097/01.tp.0000297998.33418.7e

10.1097/01.tp.0000230373.82376.46

10.1038/bmt.2009.230

10.1016/j.transci.2007.03.004

10.1111/j.1365-2141.2012.09167.x

10.1007/s00277-009-0877-5

10.1002/(SICI)1098-1101(1998)13:3<133::AID-JCA7>3.0.CO;2-Z

10.1056/NEJM199108083250605

10.1111/j.1365-3148.2006.00720.x

10.1111/j.1365-2141.2012.09032.x

10.1371/journal.pone.0010208

10.1182/blood-2005-03-0848

10.1111/j.1538-7836.2009.03568.x

10.1097/CCM.0b013e31822e9d66

10.1046/j.1365-2141.2002.03809.x

10.1038/35097008

10.1309/AJCPPNF63FLIORCI

10.1056/NEJM199108083250604

10.1111/j.1365-2141.2006.06448.x

10.1111/j.1365-2141.2012.09167.x

10.1182/blood-2011-03-341131

10.1056/NEJM199811263392203

10.1007/s11239-012-0723-9

10.1111/jth.12114

10.1111/j.1365-2141.2004.04836.x

10.1002/jca.1003

10.1007/s00404-008-0762-9

10.1016/S0889-8529(18)30165-8

10.1111/j.1444-0903.2004.00600.x

10.1080/09513590600842372

10.1002/jca.20200

10.1002/jca.20014

10.2147/TCRM.S4110

10.1111/j.1744-9987.2011.01003.x

10.1016/j.ecl.2006.09.008

10.1002/jca.20161

Piga M, 2008, Amiodarone‐induced thyrotoxicosis. A review, Minerva Endocrinol, 33, 213

10.1016/j.jemermed.2004.08.020

10.2169/internalmedicine.50.6078

10.1080/17843286.1988.11717954

10.1097/00003246-198406000-00016

10.1111/j.1365-2125.1991.tb05548.x

10.1016/j.clineuro.2007.02.006

10.1046/j.1526-0968.2002.00409.x

Chrysomallis F, 1997, Plasmapheresis in toxic epidermal necrolysis, Int J Dermatol, 36, 218, 10.1046/j.1365-4362.1997.00192.x

10.1001/archderm.1990.01670250049006

10.1016/j.jaad.2011.09.029

10.1001/archderm.136.3.323

10.1016/S0190-9622(99)70497-4

Fritsch PO, 2003, Fitzpatrick's Dermatology in General Medicine (6e), 544

10.1002/jca.21213

10.1016/j.burns.2009.06.213

10.1016/j.bjps.2004.12.007

10.1007/s001340051063

10.1111/j.1346-8138.2010.01154.x

Nomura T, 2004, Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS, AIDS, 18, 2446

Kamanabroo D, 1985, Plasmapheresis in severe drug‐induced toxic epidermal necrolysis, Arch Dermatol, 121, 1548, 10.1001/archderm.1985.01660120074023

10.1111/j.1346-8138.1997.tb02524.x

10.1177/039139889101401006

10.1111/j.1744-9987.2009.00800.x

10.1111/j.1744-9987.2008.00609.x

10.1111/j.1744-9987.1998.tb00094.x

10.1093/qjmed/hcn143

10.4997/JRCPE.2010.208

10.1111/j.1749-6632.1998.tb10973.x

10.1136/jnnp.2003.031401

10.1016/0140-6736(91)92623-A

10.1002/ana.1097

Harrower T, 2006, A case of voltage‐gated potassium channel antibody‐related limbic encephalitis, Neurology, 2, 339

10.1016/S0022-510X(00)00407-X

10.1212/WNL.50.5.1483

10.1002/jca.21233

10.1136/jnnp.2007.130039

10.1097/00004691-200411000-00008

10.1093/brain/awl084

10.1136/jnnp.65.6.857

10.1093/brain/124.12.2417

10.1007/BF00868410

10.1016/j.ncl.2010.03.024

10.1002/(SICI)1097-4598(199604)19:4<505::AID-MUS10>3.0.CO;2-O

10.1111/j.1749-6632.1998.tb10969.x

10.1093/brain/116.2.453

10.1001/archneurol.2011.2985

10.1016/0140-6736(91)90073-X

10.1212/01.wnl.0000312275.04260.a0

Rueff L, 2008, Voltage‐gated potassium channel antibody‐mediated syndromes: a spectrum of clinical manifestations, Rev Neurol Dis, 5, 65

10.1002/ana.410380505

Wintzen AR, 1994, Neuromyotonia with early response to plasmapheresis associated with proximal action myoclonus with late response to plasmapheresis, Muscle Nerve, 17, S221

10.1136/jnnp.2009.178293

10.1007/s004150050419

10.1093/brain/awh077

Vernino S, Manual of Clinical and Laboratory Immunology, 2002

10.1097/MPG.0b013e318208d0a3

10.1002/jca.20140

10.1002/jca.20186

10.1002/jca.20118

10.1046/j.1537-2995.1998.38498257369.x

10.2169/internalmedicine.42.967

10.1055/s-0031-1286056